Talaris Competitors

Delisted . USA . 
Stock . Talaris Therapeutics
TALSDelisted Stock  USD 2.98  0.10  3.25%   
Talaris Therapeutics competes with Edgewise Therapeutics, Adicet Bio, Cullinan Oncology, Vor Biopharma, and CytomX Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Talaris Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Talaris Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Talaris Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.982.982.98
Details
Intrinsic
Valuation
LowRealHigh
2.422.423.28
Details
Naive
Forecast
LowNextHigh
2.772.772.77
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.933.073.21
Details

Talaris Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Talaris Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Talaris and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Talaris Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CGEM
+ 0.92
ACET
SPRO
+ 0.9
CGEM
SPRO
+ 0.83
ACET
NUVB
+ 0.75
VOR
TIL
+ 0.72
CGEM
TIL
+ 0.69
ACET
  
High negative correlations   
TIL
- 0.63
EWTX
NLTX
- 0.56
VOR
NUVB
- 0.54
ACET
VOR
- 0.53
ACET
VOR
- 0.45
CGEM
NUVB
- 0.43
NLTX

Risk-Adjusted Indicators

There is a big difference between Talaris Stock performing well and Talaris Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Talaris Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EWTX  3.57  0.97  0.28  0.77  2.82 
(4.21)
 6.46 
(5.54)
 62.40 
ACET  3.00 (0.71) 0.00 (1.43) 0.00 
 0.00 
 6.19 
(6.54)
 23.81 
CGEM  2.87 (0.65) 0.00  119.03  0.00 
 0.00 
 5.88 
(7.24)
 17.85 
VOR  3.92 (0.04) 0.00  0.00  3.97 
(5.64)
 8.11 
(7.78)
 36.01 
CTMX  3.10 (0.08) 0.00 (0.03) 0.00 
 0.00 
 6.78 
(5.49)
 22.92 
TIL  5.77 (1.60) 0.00 (0.71) 0.00 
 0.00 
 12.77 
(10.84)
 30.36 
NLTX  2.25 (0.18) 0.00 (3.46) 0.00 
 0.00 
 4.05 
(3.53)
 27.84 
SPRO  1.90 (0.43) 0.00 (0.71) 0.00 
 0.00 
 3.45 
(4.58)
 14.92 
ASMB  3.29 (0.12) 0.00 (0.13) 0.00 
 0.00 
 8.88 
(6.83)
 21.34 
NUVB  3.56 (0.10) 0.00 (0.01) 0.00 
 0.00 
 9.48 
(8.36)
 21.30 
All Fundamental Data

Talaris Therapeutics Competitive Analysis

The better you understand Talaris Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Talaris Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Talaris Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TALS EWTX ACET CGEM VOR CTMX TIL NLTX SPRO ASMB
 3.25 
 2.98 
Talaris
 2.57 
 30.78 
Edgewise
 1.11 
 0.91 
Adicet
 7.71 
 11.60 
Cullinan
 2.55 
 0.87 
Vor
 0.91 
 1.09 
CytomX
 2.64 
 20.61 
Instil
 1.43 
 0.69 
Neoleukin
 4.49 
 0.96 
Spero
 3.80 
 15.21 
Assembly
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Moderately volatile
Not too volatile
Risky
Dangerous
Relatively risky
Very steady
Unstable
Relatively risky
Market Performance
(90 Days Performance)
Very Weak
Modest
Very Weak
Very Weak
Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
About Average
Above Average
Below Average
Very High
About Average
Above Average
Dangerous
Very Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Buy
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Hold
Strong Sell
Cautious Hold
Strong Sell
Cautious Hold
Cautious Hold
Not Rated
Strong Sell
Sell
Current Ratio
28.92
27.49
16.1
10.04
12.95
2.05
8.51
12.78
3.65
8.31
Net Asset
193.72 M
340.04 M
207.29 M
484.18 M
198.13 M
201.79 M
325.63 M
115.95 M
182.39 M
136.82 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
0.11
N/A
N/A
0.15
-2.12
EBITDA
(74.31 M)
(112.81 M)
(136.53 M)
(190.34 M)
(114.37 M)
(4.31 M)
(146.12 M)
(56.48 M)
25.77 M
(64.2 M)
Current Valuation
(28.92 M)
2.35 B
(109.71 M)
51.48 M
31.16 M
(24.04 M)
92.9 M
(35.02 M)
(17.29 M)
(6.43 M)
Price To Book
0.28
5.81
0.35
1.0
0.84
5.04
0.73
0.44
0.83
3.35
Operating Margin
N/A
N/A
N/A
N/A
N/A
0.12
N/A
N/A
-1.87
-1.43
Retained Earnings
(164.74 M)
(244.76 M)
(380.77 M)
(200.86 M)
(340.08 M)
(723.45 M)
(580.98 M)
(451.06 M)
(391.07 M)
(785.75 M)
Current Asset
N/A
N/A
352.66 M
N/A
N/A
189.75 M
N/A
289 K
7.3 M
68.37 M
Five Year Return
N/A
N/A
3.23
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
2.18
0.15
1.7
-0.12
-0.41
1.06
1.74
1.1
0.63
0.59
Number Of Employees
84
108
143
85
168
120
49
7
46
65
Shares Outstanding
42.81 M
94.69 M
82.4 M
58.23 M
68.67 M
78.26 M
6.53 M
2.35 M
54.52 M
6.36 M
Cash Flow From Operations
(60.86 M)
(91.95 M)
(93.72 M)
(134.28 M)
(100.29 M)
(56.03 M)
(82.03 M)
(45.61 M)
(32.99 M)
22.74 M
Total Debt
2.88 M
5.41 M
20.92 M
3.59 M
35.66 M
13.97 M
86.05 M
12.07 M
5.54 M
2.34 M
Return On Equity
-0.42
-0.32
-0.58
-0.27
-0.78
-54.75
-0.49
-0.38
0.26
-1.02
Z Score
24.78
N/A
N/A
N/A
N/A
N/A
N/A
-5.73
N/A
N/A
Return On Asset
-0.23
-0.22
-0.29
-0.2
-0.4
0.0233
-0.12
-0.19
0.1
-0.35
Number Of Shares Shorted
340.1 K
5.74 M
2.99 M
9.16 M
1.41 M
4.39 M
243.79 K
26.4 K
493.83 K
15.88 K
Book Value Per Share
3.49
5.18
3.93
10.8
2.22
-0.3
34.72
34.18
2.02
7.5
Current Liabilities
N/A
N/A
98.91 M
N/A
N/A
15.74 M
N/A
1.02 M
6.04 M
3.4 M
Total Asset
193.72 M
340.04 M
207.29 M
484.18 M
198.13 M
201.79 M
325.63 M
115.95 M
182.39 M
136.82 M
Debt To Equity
0.015
0.007
0.076
0.001
0.24
0.67
0.12
0.11
0.19
0.041
Short Ratio
4.01
8.93
7.04
16.75
2.99
4.32
2.29
1.7
2.08
0.41
Target Price
20.0
49.14
6.4
33.0
13.21
5.29
100.33
1.5
5.0
35.5
Shares Owned By Institutions
77.67
99.54
76.43
95.51
81.2
65.66
80.7
45.58
23.04
18.79
Market Capitalization
125.73 M
2.84 B
70.89 M
627.11 M
61.12 M
82.95 M
127.91 M
8.2 M
54.23 M
85.87 M
Price To Earning
N/A
3.45
36.84
5.23
N/A
-11.41
18.31
-4.6
81.2
-10.58
Price To Earnings To Growth
N/A
N/A
0.82
N/A
N/A
-1.8
N/A
-0.03
N/A
N/A
Price To Sales
N/A
N/A
9.72
26.88
N/A
0.66
55329.79
N/A
0.46
4.0
Net Income
(73.89 M)
(100.16 M)
(142.66 M)
(153.16 M)
(117.86 M)
(569 K)
(156.09 M)
(57.56 M)
22.81 M
(61.23 M)
Earnings Per Share
-1.97
-1.5
-1.7
-2.84
-1.64
0.16
-11.56
-12.28
0.08
-6.89
Shares Owned By Insiders
11.9
0.46
1.59
4.49
1.17
1.0
12.86
16.46
20.13
31.62
Revenue
N/A
N/A
N/A
N/A
N/A
101.21 M
N/A
N/A
96.73 M
7.16 M
Working Capital
174.15 M
310.23 M
142.99 M
452.05 M
125.23 M
27.02 M
150.2 M
88.07 M
94.06 M
94.56 M
Cash And Equivalents
207.11 M
248.4 M
260.64 M
611 M
151.09 M
194.29 M
354.61 M
116.46 M
45.4 M
116.69 M
Cash Per Share
4.97
4.99
6.11
13.4
3.97
2.94
2.73
2.73
1.29
2.41
Gross Profit
N/A
N/A
24.99 M
18.94 M
N/A
53.16 M
138 K
N/A
(42.11 M)
(63.9 M)
Day Typical Price
3.01
31.15
0.9
11.41
0.86
1.07
20.54
0.69
0.97
15.49
Accumulation Distribution
0.0325
86843.49
41199.39
80495.76
10496.27
68656.7
16232.79
0.0563
13321.49
2375.48
Market Facilitation Index
0.1
0.0
N/A
0.0
N/A
N/A
0.0
0.04
N/A
0.0
Daily Balance Of Power
(1.00)
0.302
0.1667
0.7615
(0.57)
(0.14)
0.1906
(0.25)
(1.12)
(0.48)
Period Momentum Indicator
(0.10)
0.77
0.01
0.83
(0.02)
(0.01)
0.53
(0.01)
(0.04)
(0.60)
Rate Of Daily Change
0.97
1.03
1.01
1.08
0.97
0.99
1.03
0.99
0.96
0.96
Day Median Price
3.03
31.34
0.89
11.32
0.86
1.07
20.51
0.69
0.97
15.63
Price Action Indicator
(0.10)
(0.17)
0.025
0.7
(0)
0.02
0.37
(0.01)
(0.04)
(0.72)
Relative Strength Index
53.72
54.61
38.61
34.62
61.35
53.34
35.14
33.88
36.1
47.2
Coefficient Of Variation
846.74
769.63
(605.94)
(564.67)
41841.42
(10,733)
(464.13)
(2,179)
(625.30)
(5,157)
Mean Deviation
3.42
3.57
3.0
2.87
3.92
3.1
5.77
2.25
1.9
3.29
Jensen Alpha
0.5286
0.967
(0.71)
(0.65)
(0.04)
(0.08)
(1.60)
(0.18)
(0.43)
(0.12)
Total Risk Alpha
0.4171
0.7687
(0.82)
(0.76)
(0.16)
(0.17)
(1.76)
(0.29)
(0.50)
(0.25)
Sortino Ratio
0.1545
0.2807
N/A
N/A
(0)
N/A
N/A
N/A
N/A
N/A
Downside Variance
12.04
12.04
N/A
N/A
19.46
N/A
N/A
N/A
N/A
N/A
Standard Deviation
4.82
7.75
4.16
3.64
5.68
4.07
7.14
3.7
2.57
4.87
Kurtosis
6.08
36.19
2.61
0.2528
7.09
1.02
0.0291
13.95
2.3
3.37
Potential Upside
7.32
6.46
6.19
5.88
8.11
6.78
12.77
4.05
3.45
8.88
Treynor Ratio
0.4271
0.7676
(1.43)
119.03
0.0019
(0.03)
(0.71)
(3.46)
(0.71)
(0.13)
Maximum Drawdown
27.39
62.4
23.81
17.85
36.01
22.92
30.36
27.84
14.92
21.34
Variance
23.24
60.11
17.31
13.25
32.27
16.6
51.03
13.69
6.58
23.71
Market Risk Adjusted Performance
0.4371
0.7776
(1.42)
119.04
0.0119
(0.02)
(0.70)
(3.45)
(0.70)
(0.12)
Risk Adjusted Performance
0.1021
0.1122
(0.12)
(0.13)
0.0105
7.0E-4
(0.16)
(0.03)
(0.12)
(0.01)
Skewness
1.76
5.36
0.8012
0.1067
1.89
0.3973
0.5762
(2.77)
0.7544
0.3923
Semi Deviation
3.08
2.82
N/A
N/A
3.97
N/A
N/A
N/A
N/A
N/A
Information Ratio
0.1112
0.1256
(0.17)
(0.19)
(0)
(0.02)
(0.22)
(0.05)
(0.17)
(0.03)
Value At Risk
(5.95)
(5.54)
(6.54)
(7.24)
(7.78)
(5.49)
(10.84)
(3.53)
(4.58)
(6.83)
Expected Short fall
(4.19)
(4.21)
N/A
N/A
(5.64)
N/A
N/A
N/A
N/A
N/A
Downside Deviation
3.47
3.47
N/A
N/A
4.41
N/A
N/A
N/A
N/A
N/A
Semi Variance
9.51
7.96
N/A
N/A
15.74
N/A
N/A
N/A
N/A
N/A

Talaris Therapeutics Competition Performance Charts

Five steps to successful analysis of Talaris Therapeutics Competition

Talaris Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Talaris Therapeutics in relation to its competition. Talaris Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Talaris Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Talaris Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Talaris Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Talaris Therapeutics position

In addition to having Talaris Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Natural Foods Thematic Idea Now

Natural Foods
Natural Foods Theme
Companies producing natural foods including dairy products and different types of meets. The Natural Foods theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Natural Foods Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Consideration for investing in Talaris Stock

If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
CEOs Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY